Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:diseases:ankylosing_spondylitis [01.11.2019] – [Standard treatments] sallieqhome:diseases:ankylosing_spondylitis [01.11.2019] – [Doctor's report] sallieq
Line 96: Line 96:
 Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw   (({{pubmed>long:30534822}})) Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw   (({{pubmed>long:30534822}}))
  
-===== Doctor's report ===== + 
- +
- +
-[[home:publications:blaney_autoimmunity_2010|Blaney: congress on autoimmunity 2010]] +
- +
- +
-<blockquote> +
-Case 1 is ankylosing spondylitis in a now 50 year old male. Onset was at the age of 26, initially as sacroiliitis. It progressed in a typical fashion with increasing rigidity of the spine, fusion of cervical facet joints, pain and fatigue. He also developed co-morbid conditions including chronic prostatitis, neuropathy, irritable bowel syndrome, insomnia and depression. He was unable to work full time.  He started treatment December 2005. +
- +
-He experienced waxing and waning of symptoms both physical and emotional through the first 3 years of treatment, peaking in mid 2007. Presently he is no longer depressed and is back working full time in international finance. His prostatitis has cleared as has his IBS. Bone density increased 11% in his femur and 5% in his lumbar vertebrae over the last 2 years. His Bath Ankylosing spondylitis Disease Activity Index which had risen from 8.8 to 9.2 is now 5.3.</blockquote> +
  
  
home/diseases/ankylosing_spondylitis.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.